Vancouver Clinic Earns Therapeutic License to Administer New Drug to Treat Prostate Cancer
“We are thrilled to offer this novel treatment in Canada to help prolong lives” VANCOUVER, BC, March 7, 2023 /CNW/ – INITIO Medical Group is the first private nuclear medicine facility in Canada to be awarded a therapeutic license to administer Lutetium-177-PSMA (prostate specific membrane antigen) for the treatment of advanced prostate cancer, specifically “metastatic […]
First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide.
MELBOURNE, Australia, May 1, 2023 /CNW/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illuccix® [kit for the preparation of gallium (68Ga) PSMA-11 for intravenous injection]. With Illuccix now available nationwide in Canada through Telix’s partner Isologic […]
PSMA-PET May Improve Lymph Node Dissection in Locally Advanced Prostate Cancer
Story: https://www.renalandurologynews.com/home/news/urology/prostate-cancer/psma-pet-may-improve-lymph-node-dissection-in-locally-advanced-prostate-cancer/Prostate-specific membrane antigen (PSMA)-guided radical prostatectomy (RP) can remove positive lymph nodes missed during extended pelvic lymph node dissection (ePLND) in patients with locally advanced prostate cancer, investigators suggest. In a retrospective study of 35 patients undergoing open RP with ePLND for primary treatment, preoperative PSMA positron emission tomography (PSMA-PET) detected 78 locoregional lymph node […]
Study shows benefit of PSMA-PET imaging before radical prostatectomy
Story: https://www.urologytimes.com/view/study-shows-benefit-of-psma-pet-imaging-before-radical-prostatectomyClinical guidelines currently do not recommend PSMA-PET imaging before radical prostatectomy. Patients with non-metastatic prostate cancer staged with PSMA-PET imaging before radical prostatectomy are at lower risk of early recurrence compared with patients staged with conventional imaging alone, according to findings shared during the 2023 European Association of Urology Annual Congress.1 “PSMA-PET scan helps clinicians […]
LLU researchers awarded over $5.8 million in grants from National Institutes of Health
Story: https://news.llu.edu/research/llu-researchers-awarded-over-58-million-grants-from-national-institutes-of-health Two teams of LLU researchers (from left: Dr. Carlos Casiano, Dr. Frankis Almaguel, Dr. Daliao Xiao, Dr. Charles Wang) will use their NIH grant funding to pursue their research projects.Loma Linda University researchers received over $5.8 million in grants from the National Institutes of Health (NIH). The grants support two separate research teams’ projects: […]
Real-world Experiences Associated with Treating Patients With Lutetium-177 PSMA in a High-volume Care Center – Thomas Hope
Story: https://www.urotoday.com/video-lectures/asco-gu-2023/video/3297-real-world-experiences-associated-with-treating-patients-with-lutetium-177-psma-in-a-high-volume-care-center-thomas-hope.html March 22, 2023 Thomas Hope joins Phillip Koo to discuss real-world challenges associated with patient selection, laboratory abnormalities, and workflow issues in treating patients with lutetium-177 PSMA in a high-volume care center. He also talks about the need to identify when to stop therapy and how to spread out doses effectively while minimizing […]
Research uncovers alternate mechanism for producing key protein in metastatic prostate cancer
Story: https://www.dana-farber.org/newsroom/news-releases/2023/research-uncovers-alternate-mechanism-for-producing-key-protein-in-metastatic-prostate-cancer/ Research Summary Study Title: Landscape of Prostate-Specific Membrane Antigen Heterogeneity and Regulation in AR-positive and AR-negative Metastatic Prostate Cancer Publication: Nature Cancer, April 10, 2023, 11:00am EST https://www.nature.com/articles/s43018-023-00539-6 Dana-Farber Cancer Institute authors Himisha Beltran, MD; Martin Bakht, PhD Impact: t has long been known that the androgen receptor (AR) – a structure that triggers […]
Alpha Tau treats first patient in pancreatic cancer feasibility study
Story: https://www.medicaldevice-network.com/news/alpha-tau-pancreatic-cancer-feasibility/ The patient was treated using Alpha DaRT at the Jewish General Hospital (JGH) in Montreal, Canada. Fine needle aspiration of well-differentiated pancreatic adenocarcinoma. Credit: Ed Uthman / commons.wikimedia.org. sraeli medical device firm Alpha Tau Medical has announced that the first pancreatic cancer patient has been treated using Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) in […]
MRI-targeted biopsy finds clinically significant prostate cancers
Story: https://www.auntminnie.com/index.aspx?sec=sup&sub=mri&pag=dis&ItemID=139772 By Kate Madden Yee, AuntMinnie.com staff writer April 6, 2023 — MRI-targeted biopsy prompted by elevated prostate-specific antigen (PSA) levels identifies fewer clinically insignificant prostate cancers than systemic biopsy, according to a paper published April 4 in the Annals of Internal Medicine. And it’s comparable to a systemic biopsy protocol for detecting clinically significant disease, wrote […]
New Nuclear Medicine Therapy Cures Human Non-Hodgkin Lymphoma in Preclinical Model
Story: https://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=43664 Reston, VA—A new nuclear medicine therapy can cure human non-Hodgkin lymphoma in an animal model, according to research published in the April issue of The Journal of Nuclear Medicine. A single dose of the radioimmunotherapy, [177Lu]Lu-ofatumumab, was found to quickly eliminate tumor cells and extend the life of mice injected with cancerous cells for […]